What is the dose of Eptoin (Phenytoin) in head injury?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Phenytoin (Eptoin) Dosing for Head Injury

For seizure prophylaxis in head injury, administer a loading dose of 15-20 mg/kg IV in pediatric patients or 10-15 mg/kg IV in adults, infused at a rate not exceeding 1-3 mg/kg/min (or 50 mg/min, whichever is slower), followed by maintenance doses of 100 mg every 6-8 hours. 1

Loading Dose Administration

Pediatric Patients

  • Loading dose: 15-20 mg/kg IV 2, 1
  • Infusion rate: Maximum 1-3 mg/kg/min or 50 mg/min, whichever is slower 2, 1
  • This dosing achieves therapeutic serum concentrations between 10-20 mcg/mL 1

Adult Patients

  • Loading dose: 10-15 mg/kg IV 1
  • Infusion rate: Maximum 50 mg/min (approximately 20 minutes for a 70-kg patient) 1
  • Alternative dosing up to 18-20 mg/kg may be used, with 97% of patients achieving therapeutic levels immediately after infusion 3, 4

Maintenance Dosing

  • 100 mg IV or oral every 6-8 hours following the loading dose 1
  • For oral maintenance in adults: typically 300-400 mg/day (4-6 mg/kg/day) divided into 1-3 doses 4
  • Target therapeutic serum total concentrations: 10-20 mcg/mL (unbound: 1-2 mcg/mL) 1

Critical Safety Monitoring

Continuous cardiac and respiratory monitoring is mandatory during administration 2, 1:

  • Monitor ECG continuously for bradycardia, arrhythmias, and heart block 2, 1
  • Monitor blood pressure for hypotension 2, 1
  • Observe for respiratory depression 1
  • Reduce infusion rate if heart rate decreases by 10 beats/min 2

Administration Technique

  • Administer through large-gauge catheter into large peripheral or central vein 1
  • Flush with sterile saline before and after each dose to prevent local venous irritation 1
  • Dilute in normal saline only (never dextrose-containing solutions due to precipitation) 2, 1
  • If diluted for infusion, final concentration should be ≥5 mg/mL 1

Important Clinical Context

Efficacy Evidence for Head Injury

The evidence for phenytoin prophylaxis in head injury shows effectiveness only for early seizures (first 7 days) 5:

  • Phenytoin reduces seizures in the first week after severe head injury (3.6% vs 14.2% with placebo, p<0.001) 5
  • No benefit beyond the first week: 21.5% phenytoin group vs 15.7% placebo group had seizures between day 8 and year 1 5
  • In pediatric head injury, one study found no significant benefit (7% phenytoin vs 5% placebo experienced seizures within 48 hours) 6

However, conflicting evidence exists, with one older study showing failure to prevent early posttraumatic seizures 7, while another suggested reduced incidence with proper dosing regimen 8.

Common Pitfalls to Avoid

  • Never use intramuscular route for acute seizure management due to erratic absorption (peak levels may require up to 24 hours) 1
  • Never exceed recommended infusion rates - rapid administration causes hypotension, bradyarrhythmias, and cardiac arrest 2, 4
  • Never mix with dextrose solutions - causes precipitation 2, 1
  • Neonates have increased toxicity risk due to decreased protein binding; phenobarbital is preferred in this population 2

Special Populations

Patients with renal/hepatic disease or hypoalbuminemia 1:

  • Monitor unbound (free) phenytoin concentrations rather than total levels
  • These patients have increased fraction of unbound phenytoin

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Dosis Recomendada de Fenitoína para el Estado Epiléptico

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Phenytoin Dosage Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.